Korean J Ophthalmol > Volume 40(4); 2026 > Article
Cho, Kook, Park, and Ji: Effectiveness of Ultrathin 40-Gauge Needles for Intravitreal Injections

Abstract

Purpose

To compare pain perception and immediate post-procedural complications of intravitreal injections (IVIs) performed with conventional 30-gauge needles versus ultrathin 40-gauge needles.

Methods

This single-center, retrospective crossover study reviewed consecutive patients who underwent serial IVIs for neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, myopic choroidal neovascularization, or other indications between April and October 2020. Each patient received one injection with a 30-gauge needle and one with a 40-gauge needle—either to the fellow eye on the same day or to the same eye 1-month apart. Injections (0.05 mL bevacizumab, ranibizumab, or aflibercept) were administered in an operating room by a single surgeon following the guidelines of Avery et al. Pain was recorded immediately postinjection on a visual analog scale (VAS). Subconjunctival hemorrhage (SCH) and vitreous reflux (VR) were graded 0 to 4.

Results

Mean age was 69.3 ± 11.5 years; 69.0% were men. VAS pain scores were significantly lower with 40-gauge needles than with 30-gauge needles (2.33 ± 1.26 vs 4.02 ± 1.73; paired difference [mean ± standard error], −1.69 ± 0.33; p < 0.001). Median VR grade declined from 2 (interquartile range [IQR], 2-3) to 0 (IQR, 0-1) with 40-gauge needles (p < 0.001). SCH grade did not differ between gauges (median [IQR], 0 [0-1]; p = 0.928). No injection-related adverse events occurred.

Conclusions

Using an ultrathin 40-gauge needle for IVIs significantly reduces patient-reported pain and VR without increasing subconjunctival hemorrhage. These findings support the integration of 40-gauge needles into routine IVI practice to enhance long-term patient adherence and treatment efficacy.

Intravitreal injection (IVI) delivers pharmacologic agents directly into the vitreous cavity, producing high intraocular drug concentrations while minimizing systemic exposure. It is now the standard of care for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), myopic choroidal neovascularization (CNV), and other posterior-segment diseases. As the armamentarium of anti-vascular endothelial growth factor (anti-VEGF) and adjunctive agents continues to grow, worldwide IVI volumes are projected to increase further [1,2]. Although generally safe, IVI is not without risk. Reported procedure-related adverse events include subconjunctival hemorrhage, transient or sustained intraocular pressure elevation, uveitis, intraocular hemorrhage, retinal detachment, and infectious endophthalmitis [3]. Beyond these potential risks, anti-VEGF IVIs often require repetitive treatments over several years for patients [4,5], making it crucial to reduce patient burden during the procedure. Consequently, optimizing the patient experience, particularly minimizing pain, has become an essential component of long-term treatment adherence.
Various strategies have been explored to alleviate procedural pain, among which modification of needle gauge represents a key modifiable factor. Prior investigations have suggested a potential relationship between needle diameter and pain; however, the evidence has been inconsistent, with most studies limited to comparisons between needles differing by only 2 to 4 gauge, corresponding to relatively minor variations in outer diameter [6-9]. By contrast, ultrathin 40-gauge needles (outer diameter approximately 100-120 μm) offer a substantially greater reduction in caliber, yet their influence on procedural comfort and early complications remains insufficiently characterized.
The present retrospective crossover study was conducted to elucidate: (1) whether 40-gauge needles reduce patient-reported pain compared with conventional 30-gauge needles, and (2) how needle miniaturization influences immediate post-injection events—specifically subconjunctival hemorrhage, which may affect cosmetic satisfaction and comfort, and vitreous reflux, which could compromise delivered drug dose. By controlling inter-individual variability within the same patients, we aimed to provide a clearer understanding of the clinical trade-offs associated with adopting ultrathin needles for IVI.

Materials and Methods

Ethics statement

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Chonnam National University Hospital (No. CNUH-2025-266). The requirement for informed consent was waived due to the use of deidentified data and the retrospective nature of the study.

Study design and participants

This single-center, retrospective crossover study reviewed the medical records and procedure videos of consecutive patients who underwent IVI therapy at our institution between April and October 2020. Eligible eyes had a clinical indication for IVI—nAMD, DME, RVO, myopic CNV, or others—and the patient was able to comprehend and report procedural pain. Exclusion criteria were active ocular infection or inflammation, any preexisting ocular pain, a contraindication to IVI, and previous vitrectomy (which may influence vitreous reflux) on the study eye or any intraocular surgery performed during the injection interval.
For the within-patient comparison, patients were included if they had exposure to both needle gauges during the study period. When only one eye required treatment, two successive injections were administered to the same eye 1 month apart; when both eyes required treatment, injections were delivered to each eye on the same day. In routine clinical practice, injections were performed using both 30- and 40-gauge needles, and the gauge order (30-gauge vs. 40-gauge) was alternated at the injector’s discretion and documented at the time of the procedure. For each patient, the same therapeutic agent was used for both injections.

Intravitreal injection procedure

All procedures were performed in the operating room by a single experienced retinal specialist following the protocol described by Avery et al. [10]. After achieving adequate mydriasis, a sterile lid speculum was inserted and topical anesthesia applied with 0.5% proparacaine hydrochloride. The periocular skin and conjunctival fornix were disinfected with 5% povidone-iodine. The injection site was marked 3.5 mm posterior to the limbus in pseudophakic/ aphakic eyes and 4.0 mm in phakic eyes, midway between the vertical and horizontal recti. For patients requiring bilateral injections, each eye was treated as an independent procedure with full re-preparation between eyes.
Either a 30-gauge PrecisionGlide needle (outer diameter 300 μm, length 13 mm; Becton Dickinson) or a 40-gauge needle-VN (total length 20 ± 1 mm, INCYTO) was attached to a 1-mL syringe prefilled with bevacizumab, ranibizumab, or aflibercept. The 40-gauge needle has a hybrid configuration comprising a 27-gauge base segment (15 mm) and a 40-gauge terminal tip (5 mm, outer diameter 100-120 μm) (Fig. 1A, 1B). With the bevel facing upward, the needle was introduced perpendicular to the sclera, with only the 5-mm ultrathin tip of the 40-gauge needle penetrating intraocularly. The drug was injected slowly, and the needle was withdrawn along the same track to minimize vitreous reflux.

Outcome measures

1) Pain assessment

Immediately after each injection, patients rated procedural pain using a visual analog scale (VAS) ranging from 0 points (no pain at all) to 10 points (the most severe level of pain that a patient could experience).

2) Subconjunctival hemorrhage and vitreous reflux

All procedures were performed using a surgical microscope with video recording. Immediately following each injection, the operator documented the presence and severity of subconjunctival hemorrhage and vitreous reflux in the medical record; these assessments were subsequently verified through systematic review of the recorded videos. Both complications were graded on an ordinal 0 to 4 scale based on the maximal diameter of the subconjunctival hemorrhage or vitreous reflux bleb (grade 0, none; grade 1, 1 mm; grade 2, 2 mm; grade 3, 3 mm; grade 4, ≥4 mm) (Figs. 2A-2D, 3A-3D). If subconjunctival hemorrhage or vitreous reflux reached grade 4, gentle pressure with a sterile cotton swab was planned to minimize drug loss; however, no such cases occurred in this series.

Statistical analysis

Continuous variables are presented as mean ± standard deviation (SD). Paired t-tests were employed to compare VAS scores between 30- and 40-gauge needles. Because subconjunctival hemorrhage and vitreous reflux grades are ordinal, inter-gauge differences were assessed with the Wilcoxon signed-rank test. Analyses were conducted using SPSS ver. 18.0 (IBM Corp.). Two-sided p-values <0.05 were considered statistically significant.

Results

Forty-two patients received paired injections and were included in the analysis. The mean age was 69.3 ± 11.5 years, and 29 participants (69.0%) were male. Treatment indications comprised nAMD in 31 eyes (73.8%), DME in 3 (7.1%), RVO in 2 (4.8%), myopic CNV in 1 (2.4%), and other diagnoses in 5 (11.9%). Injected agents were aflibercept (47.6%), ranibizumab (33.3%), and bevacizumab (19.0%). Thirty-seven patients received two successive injections to the same eye 1 month apart, whereas five underwent bilateral injections on a single day; each patient thus served as their own control (Table 1).
Across the cohort, VAS pain scores were significantly lower with ultrathin 40-gauge needles than with conventional 30-gauge needles (mean ± SD, 2.33 ± 1.26 vs. 4.02 ± 1.73; mean paired difference ± standard error, −1.69 ± 0.33; t = 5.19; 95% confidence interval, −2.34 to −1.03; p < 0.001). Vitreous reflux likewise decreased, with median grade falling from 2 (interquartile range [IQR], 2-3) after 30-gauge injections to 0 (IQR, 0-1) after 40-gauge injections (Wilcoxon signed-rank Z = −3.62; p < 0.001). In contrast, subconjunctival hemorrhage showed no meaningful difference between gauges (median grade [IQR], 0 [0-1] for both; p = 0.928) (Table 2). No injection-related severe adverse events—such as endophthalmitis, retinal break, sustained intraocular pressure rise, or severe pain requiring additional anesthesia—were observed. Adverse events were assessed on the day following the injection, and subsequent follow-up confirmed the absence of any complications.

Discussion

This retrospective crossover study shows that substituting an ultrathin 40-gauge needle for the conventional 30-gauge device yields clinically relevant benefits during IVI. A two-thirds reduction in outer diameter produced a significant decrease in patient-reported pain and an even greater reduction in vitreous reflux, while the incidence of subconjunctival hemorrhage remained unchanged. Because anti-VEGF therapy frequently requires lifelong, repetitive dosing, any strategy that enhances comfort and preserves delivered dose has the potential to improve long-term adherence and visual outcomes.
Currently, the 30-gauge needle is the most used device for IVIs. Although prior work has suggested an association between needle diameter and pain perception, the evidence remains inconsistent [11]. Aderman et al. [12] and Eaton et al. [13] compared 30-gauge with 33-gauge needles and found no statistically significant differences in pain scores between the two groups. By contrast, Sasajima et al. [14] reported that patients experienced less pain with 34-gauge needles compared with 30-gauge, and a South Korean study similarly demonstrated lower pain scores with 40-gauge compared to 30-gauge needles [15]. These conflicting findings are likely attributable to the relatively small caliber differences assessed in most prior studies. To address this limitation, the present study compared 30-gauge needles (outer diameter approximately 300 μm) with ultrathin 40-gauge needles (outer diameter approximately 100-120 μm), representing a substantially greater reduction in caliber (approximately 60%-67%). We further sought to objectively and reliably evaluate postprocedural pain using the VAS, a patient-friendly instrument that is particularly suited for elderly individuals who constitute a major proportion of this population [16]. Using this approach, we demonstrate that the use of 40-gauge needles significantly reduced postinjection pain.
The observed pain reduction is clinically meaningful from the patient’s perspective. The minimal clinically important difference (MCID) for acute pain has been established as 1.4 to 1.8 points on a 10-point VAS or a relative reduction of at least 23.0% [17,18]. Our study demonstrated a 1.69-point decrease (from 4.02 to 2.33), corresponding to a 42.0% reduction from baseline. Both metrics exceed the established MCID thresholds, indicating that the pain reduction is clinically perceptible and meaningful to patients undergoing IVI.
Previous studies have suggested that demographic factors such as age and sex may influence pain perception during IVI, but their findings have been inconsistent. Rifkin and Schaal [19] reported lower pain scores in female patients and in individuals aged ≥66 years, whereas Shin et al. [20] observed higher pain scores in women and no significant association with age. In contrast, Damasceno et al. [21] found no correlation between pain and either age or sex. Such discrepancies highlight the potential for demographic and inter-individual variability to confound the assessment of procedural discomfort. To minimize these effects, we adopted a within-subject crossover design in which each patient received both 30- and 40-gauge injections—either bilaterally on the same day or sequentially 1 month apart. The gauge order was alternated at the injector’s discretion. This approach reduced the influence of age-, sex-, and patient-specific factors, while also controlling for habituation, anxiety, and other effects inherent to repeated procedures. Through this design, we aimed to more clearly isolate the impact of needle gauge on pain perception.
Given the subjective nature of pain assessment and the methodological limitations of prior studies, our approach offers several advantages. First, by evaluating the same patients, we were able to minimize inter-individual variability in pain perception, which can be influenced by prior experiences, psychological state, and expectation effects [22]. Second, by administering the same medication to each patient across injections, we eliminated potential confounding from drug-related differences. Previous studies have shown that bevacizumab is associated with higher pain scores compared to aflibercept or ranibizumab [23], and that aflibercept causes more discomfort than ranibizumab [24], likely due to compositional or pH-related factors. By controlling such variables, our design enabled a more direct evaluation of the influence of needle gauge on pain.
Subconjunctival hemorrhage, although cosmetically troubling for some patients, was not affected by needle caliber in our series. This result is consistent with evidence that systemic factors—hypertension, diabetes, and anticoagulant therapy—and transient periprocedural spikes in arterial pressure are the principal determinants of hemorrhagic risk, rather than the scleral tract diameter itself [25,26]. Accordingly, the transition to 40-gauge needles should not engender additional bleeding concerns in routine practice.
Vitreous reflux fell dramatically with 40-gauge needles, a finding with two important implications. First, because the intravitreal aliquot is small (approximately 0.05 mL), minimizing reflux helps ensure that the intended therapeutic dose reaches the posterior segment. Second, a smaller scleral tract may reduce the theoretical risk of pathogen ingress and subsequent endophthalmitis—the most feared complication of the procedure [27]. Although no infections occurred in the present series, larger cohorts and extended follow-up are required to substantiate this potential safety advantage.
This study has several limitations that should be considered when interpreting the results. First, this was a retrospective study; however, the data were collected as part of a structured internal clinical practice evaluation conducted when the 40-gauge needle was introduced at our institution. Outcome measures were predefined, and all data—including pain scores, video documentation, and grading of subconjunctival hemorrhage and vitreous reflux—were recorded contemporaneously during routine clinical care, prior to the conception of the current analysis. These efforts were made to ensure the objectivity and completeness of the data, minimizing the risk of retrospective bias in data collection. Institutional review board approval was subsequently obtained after recognizing the scientific value of the systematically documented data. Second, the modest sample size and single-center design limit the generalizability of our findings and preclude assessment of long-term outcomes such as intraocular pressure fluctuations and late-onset adverse events. Third, although the inclusion of heterogeneous retinal diseases reflects real-world clinical practice, the limited subgroup sizes hinder comprehensive disease-specific analyses, which may introduce confounding. Fourth, drug histories, including anticoagulant use (which may also influence subconjunctival hemorrhage), were not systematically documented at each IVI time point, which we acknowledge as a limitation. However, given that injections were performed in the same patients either on the same day or at a 1-month interval, we believe there is little difference in systemic medication use between the groups (30-gauge vs. 40-gauge). This paired design enables within-subject comparisons that are independent of anticoagulant status. Fifth, because gauge order was alternated at the injector’s discretion rather than randomized, we cannot exclude order- or period-related effects (e.g., anxiety reduction with repeat procedures). Finally, our grading method based on maximal bleb diameter for vitreous reflux and subconjunctival hemorrhage, while practical and aligned with previous studies, may underestimate true reflux occurrence, especially when reflux occurs without bleb formation due to vitreous liquefaction.
Regarding 40-gauge needles, several clinical limitations are noteworthy. Their higher cost may increase patient burden. Due to their thin and delicate structure, 40-gauge needles can bend or deform during scleral penetration, complicating injections. Moreover, the small lumen may clog when injecting suspensions with larger particles such as triamcinolone. Nevertheless, the significant reduction in injection pain with 40-gauge needles represents an important clinical advantage, making them a valuable option despite these challenges.
In summary, ultrathin 40-gauge needles provide meaningful clinical benefits during IVIs by significantly reducing patient-reported pain and vitreous reflux without increasing subconjunctival hemorrhage. This simple modification enhances patient comfort and may improve drug delivery efficiency in managing chronic retinal diseases. Future multicenter studies with larger cohorts and longer follow-ups are needed to confirm these findings and further optimize clinical practice.

Notes

Conflicts of Interest

None.

Acknowledgements

None.

Funding

None.

References

1. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009;29:875-912.
crossref pmid
2. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013;27:787-94.
crossref pmid pmc pdf
3. Ramos MS, Xu LT, Singuri S, et al. Patient-reported complications after intravitreal injection and their predictive factors. Ophthalmol Retina 2021;5:625-32.
crossref pmid
4. Gerding H. Long-term results of intravitreal anti-VEGF injections in wet AMD: a meta-analysis. Klin Monbl Augenheilkd 2016;233:471-4.
crossref pmid
5. Shahsuvaryan ML. Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion. Int J Ophthalmol 2012;5:759-70.
pmid pmc
6. Butler ET, Bjerager J, Eriksen NS, et al. Effect of needle gauge size on pain during intravitreal anti-VEGF injection: a systematic review and network meta-analysis. Ophthalmol Ther 2024;13:801-17.
crossref pmid pmc pdf
7. Loureiro M, Matos R, Sepulveda P, Meira D. Intravitreal injections of Bevacizumab: the impact of needle size in intraocular pressure and pain. J Curr Glaucoma Pract 2017;11:38-41.
crossref pmid pmc
8. Alshahrani ST, Rubin U, Gupta V, et al. Reflux, intraocular pressure variation and pain following intravitreal ranibizumab injections using 30-gauge or 32-gauge needles for patients with retinal pathologies: a randomized clinical trial. Cureus 2021;13:e14320.
crossref pmid pmc
9. Guler M, Bilgin B, Capkin M, et al. Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. Korean J Ophthalmol 2015;29:190-4.
crossref pmid pmc
10. Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina 2014;34:Suppl 12. S1-18.
pmid
11. van Asten F, van Middendorp H, Verkerk S, et al. Are intravitreal injections with ultrathin 33-G needles less painful than the commonly used 30-G needles? Retina 2015;35:1778-85.
crossref pmid
12. Aderman CM, Rahimy E, Obeid A, et al. Comparing 33-gauge versus 30-gauge needles for intravitreal injections. Ophthalmol Retina 2018;2:1078-9.
crossref pmid
13. Eaton AM, Gordon GM, Wafapoor H, et al. Assessment of novel guarded needle to increase patient comfort and decrease injection time during intravitreal injection. Ophthalmic Surg Lasers Imaging Retina 2013;44:561-8.
crossref pmid
14. Sasajima H, Tsuboi K, Ono H, et al. A randomized trial of a short 34-gauge needle for intravitreal injections. Ophthalmology 2018;125:947-8.
crossref pmid
15. Lee SK, Kim WH, Kim SJ, Park JS. Ocular pain according to needle diameter during intravitreal injection. J Korean Ophthalmol Soc 2020;61:1042-7.
crossref pdf
16. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983;17:45-56.
crossref pmid
17. Todd KH, Funk JP. The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 1996;3:142-6.
crossref pmid
18. Bijur PE, Latimer CT, Gallagher EJ. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad Emerg Med 2003;10:390-2.
crossref pmid
19. Rifkin L, Schaal S. Factors affecting patients’ pain intensity during in office intravitreal injection procedure. Retina 2012;32:696-700.
crossref pmid
20. Shin SH, Park SP, Kim YK. Factors associated with pain following intravitreal injections. Korean J Ophthalmol 2018;32:196-203.
crossref pmid pmc pdf
21. Damasceno NA, Oliveira JA, Yannuzzi NA, et al. Potential risk factors for ocular pain in patients undergoing multiple intravitreal injections of anti-vascular endothelial growth factor. Clin Ophthalmol 2024;18:1691-9.
crossref pmid pmc pdf
22. Koyama T, McHaffie JG, Laurienti PJ, Coghill RC. The subjective experience of pain: where expectations become reality. Proc Natl Acad Sci U S A 2005;102:12950-5.
crossref pmid pmc
23. Inaltekin A, Bozkurt E, Kivrak Y. Factors associated with pain level in patients receiving intravitreal injection. J Curr Ophthalmol 2021;33:323-9.
crossref pmid pmc
24. Bilgin B, Bilak S. Assessment of patient pain experience during intravitreal ranibizumab and aflibercept injection. Middle East Afr J Ophthalmol 2019;26:55-9.
crossref pmid pmc
25. Tarlan B, Kiratli H. Subconjunctival hemorrhage: risk factors and potential indicators. Clin Ophthalmol 2013;7:1163-70.
pmid pmc
26. Yun C, Oh J, Hwang SY, et al. Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 2015;253:1465-70.
crossref pmid pdf
27. Chen SD, Mohammed Q, Bowling B, Patel CK. Vitreous wick syndrome: a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana. Am J Ophthalmol 2004;137:1159-60.
crossref pmid

Fig. 1
Structural characteristics of the 40-gauge needle used for intravitreal injection. (A) Photograph of the 40-gauge needle assembly. The circle highlights the ultrathin needle tip. (B) Schematic diagram showing the needle configuration: 27-gauge proximal hub and shaft (15 mm) connected to a 40-gauge distal tip segment (5 mm).
kjo-2025-0134f1.jpg
Fig. 2
Grading scale for vitreous reflux based on the maximal diameter of the conjunctival bleb observed immediately after injection. The arrows highlight the conjunctival bleb, and the dotted circles outline the area used for measurement of the maximal bleb diameter. (A) Grade 0 indicates no visible reflux. (B) Grade 1 shows a bleb of approximately 1 mm in diameter. (C) Grade 2 shows a bleb of approximately 2 mm. (D) Grade 3 shows a bleb of approximately 3 mm. No grade 4 (≥4 mm) cases were observed.
kjo-2025-0134f2.jpg
Fig. 3
Grading scale for subconjunctival hemorrhage based on its maximal diameter. The arrows highlight the subconjunctival hemorrhage, and the dotted circles outline the area used for measurement of the maximal hemorrhage diameter. (A) Grade 0 indicates no hemorrhage. (B) Grade 1 shows hemorrhage of approximately 1 mm in diameter. (C) Grade 2 shows hemorrhage of approximately 2 mm. (D) Grade 3 shows hemorrhage of approximately 3 mm. No grade 4 (≥4 mm) cases were observed.
kjo-2025-0134f3.jpg
Table 1
Baseline characteristics of the patients
Characteristic Value
Age (yr) 69.3 ± 11.5
Sex
 Male 29
 Female 13
Diagnosis
 AMD 31
 DME 3
 RVO 2
 Myopic CNV 1
 Others 5
Injected agent
 Bevacizumab 8
 Ranibizumab 14
 Aflibercept 20
Injection type
 Unilateral injections at monthly intervals 37
 Bilateral injections on the same day 5

Values are presented as mean ± standard deviation or number only.

AMD = age-related macular degeneration; DME = diabetic macular edema; RVO = retinal vein occlusion; Myopic CNV = myopic choroidal neovascularization.

Table 2
Comparison of outcomes between 30- and 40-gauge needle injections
Parameter Group p-value

30-Gauge 40-Gauge
Pain score (VAS) 4.02 ± 1.73 2.33 ± 1.26 <0.001*
Vitreous reflux (grade) 2.26 ± 0.87 0.31 ± 0.71 <0.001†
Subconjunctival hemorrhage (grade) 0.63 ± 1.01 0.67 ± 0.93 0.928†

Values are presented as mean ± standard deviation.

VAS = visual analog scale.

* Paired t-test;

† Wilcoxon signed-rank test.



ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#1001, Jeokseon Hyundai BD
130, Sajik-ro, Jongno-gu, Seoul 03170, Korea
Tel: +82-2-2266-7397    Fax: +82-2-2277-5194    E-mail: kos@ijpnc.com                

Copyright © 2026 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next